J&J mops up $900M in waste, writing off the last big chunk of the $1.75B it spent to acquire Alios

Back in the fall of 2014, Alios looked like quite a find for J&J, with its lead RSV drug and some early stage hep C programs as a group of rivals fought over the blockbuster market that awaited the winner of that contest.